{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-24-000046","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.456324+00:00","generated_at":"2026-05-30T07:22:34.597274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere reports Q3 net loss $54.8M; FILSPARI sales $35.6M, full FDA approval in IgAN","bullets":["Net product sales $61.0M (FILSPARI $35.6M); 505 new PSFs in Q3; 2,989 total since launch.","Full FDA approval for FILSPARI in IgAN on Sept 5, 2024; broader label and orphan exclusivity to 2031.","R&D $51.7M, SG&A $65.6M; net loss $54.8M ($0.70/share); cash $277.4M.","sNDA submitted to modify liver monitoring; Type C meeting with FDA scheduled for FSGS path.","Voluntary halt of enrollment in Phase 3 HARMONY (pegtibatinase) due to manufacturing scale-up; restart expected 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-24-000046","json":"https://secwatch.observer/filing/0001438533-24-000046.json","markdown":"https://secwatch.observer/filing/0001438533-24-000046.md","text":"https://secwatch.observer/filing/0001438533-24-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000046/0001438533-24-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853324000046/tvtx-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:22:34.597274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}